Phospho-Aurora A (Thr288)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 3050R
英文名称Phospho-Aurora A (Thr288)
中文名称磷酸化有丝分裂激酶A抗体
别 名Aurora A (phospho T288): Aurora A (phospho-Thr288); p-Aurora A(T288); Aurora A (phospho T288): Aurora A (phospho-Thr288); p-Aurora A(T288); AIK; ARK-1; ARK1; AURA; AURKA; Aurora 2; Aurora A; Aurora A; Aurora Family Kinase 1; aurora kinase A; Aurora Related Kinase 1; Aurora-related kinase 1; Aurora/IPL1 Like Kinase; Aurora/IPL1 Related Kinase 1; Aurora/IPL1-related kinase 1; AURORA2; AYK1; BRAK; Breast Tumor Amplified Kinase; Breast tumor-amplified kinase; BTAK; hARK1; IAK; IPL1 Aurora Related Kinase 1; IPL1 Related Kinase; MGC34538; OTTHUMP00000031340; OTTHUMP00000031341; OTTHUMP00000031342; OTTHUMP00000031343; OTTHUMP00000031344; OTTHUMP00000031345; OTTHUMP00000166071; OTTHUMP00000166072; PPP1R47; Protein phosphatase 1, regulatory subunit 47; Serine/threonine kinase 15; Serine/threonine kinase 6; Serine/threonine kinase; Serine/threonine kinase; Serine/threonine-protein kinase 15; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase aurora-A; STK15; STK6; STK6_HUMAN; STK7.
JournalPMIDIFApplicationThe Journal of experimental medicine (2014)2533228613.9120WB
说 明 书100ul
产品类型磷酸化抗体
研究领域细胞生物 神经生物学 信号转导 激酶和磷酸酶
抗体来源Rabbit
克隆类型Polyclonal
Phospho-Aurora A (Thr288)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量48kDa
性 状Lyophilized or Liquid
浓 度1mg/ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human Aurora A around the phosphorylation site of Thr288:RT(p-T)LC
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-Aurora A (Thr288)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
Aurora A plays a role in cell cycle regulation during anaphase and/or telophase, in relation to the function of the centrosome/spindle pole region during chromosome segregation. Aurora A plays a key role during tumor development and progression and is overexpressed in many human cancers including breast, ovarian and colorectal. Aurora A is viewed as a potential target for anticancer drug treatment.
Function:
Contributes to the regulation of cell cycle progression. Required for normal mitosis. Associates with the centrosome and the spindle microtubules during mitosis and functions in centrosome maturation, spindle assembly, maintenance of spindle bipolarity, centrosome separation and mitotic checkpoint control. Phosphorylates numerous target proteins, including ARHGEF2, BRCA1, KIF2A, NDEL1, PARD3, PLK1 and BORA. Regulates KIF2A tubulin depolymerase activity (By similarity). Required for normal axon formation. Plays a role in microtubule remodeling during neurite extension. Important for microtubule formation and/or stabilization.
Subunit:
Interacts with FBXL7 (By similarity). Interacts with CPEB1, JTB, TACC1, TPX2, PPP2CA, as well as with the protein phosphatase type 1 (PP1) isoforms PPP1CA, PPP1CB and PPP1CC. Interacts also with its substrates ARHGEF2, BORA, BRCA1, KIF2A, PARD3, and p53/TP53. Interaction with BORA promotes phosphorylation of PLK1. Interacts with PIFO. Interacts with GADD45A, competing with its oligomerization. Interacts (via C-terminus) with AUNIP (via C-terminus). Identified in a complex with AUNIP and NIN. Interacts with FRY; this interaction facilitates AURKA-mediated PLK1 phosphorylation.
Subcellular Location:
Cytoplasm, cytoskeleton, centrosome. Cytoplasm, cytoskeleton, spindle pole. Note=Detected at the neurite hillock in developing neurons (By similarity). Localizes at the centrosome in mitotic cells from early prophase until telophase, but also localizes to the spindle pole MTs from prophase to anaphase. Moves to the midbody during both telophase and cytokinesis. Associates with both the pericentriolar material (PCM) and centrioles.
Phospho-Aurora A (Thr288)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-Aurora A (Thr288)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 ADAM18 去整合素样金属蛋白酶18抗体
合格 ADAM2 去整合素样金属蛋白酶2抗体
合格 ADAM23 去整合素样金属蛋白酶23抗体
合格 合格 ADAM28 去整合素样金属蛋白酶28抗体
合格 ADAMTS13 整合素样金属蛋白酶与凝血酶13型抗体
合格 合格 ADAMTSL4 整合素样金属蛋白酶与凝血酶样4蛋白抗体
合格 KLK6 激肽释放酶6抗体
合格 CDCP1 CD318抗体
合格 合格 Endomucin 内皮粘蛋白EMCN抗体
合格 Lumican 基膜聚糖蛋白抗体
合格 ST14 丝氨酸蛋白酶14/膜型丝氨酸蛋白酶1抗体
合格 合格 HIF3 alpha 缺氧诱导因子3α/HIF-3α抗体
合格 HIFPH4 缺氧诱导因子脯氨酰4羟化酶抗体
合格 ADORA2B 腺苷A2b受体/神经生长因子1受体抗体
合格 CYPA 亲环蛋白（亲环素）PPIA抗体
合格 合格 Calreticulin 钙网蛋白抗体
合格 Annexin A7 膜粘连蛋白7抗体
合格 ANGPTL3 血管生成素样蛋白3抗体
合格 ANP32C 致瘤磷蛋白32相关蛋白1抗体
合格 KLHL7 kelch样蛋白7抗体
合格 PBOV1 前列腺癌和乳腺癌高表达蛋白抗体
合格 SERINC3 丝氨酸合并蛋白3抗体（肿瘤差异表达蛋白）
合格 RNF56 环指蛋白56抗体
合格 RASA3 Ras-GTP酶激活蛋白3抗体
合格 Styk1 丝氨酸/苏氨酸/酪氨酸激酶STYK1抗体
合格 B MyB 转录因子MYB相关蛋白B抗体
合格 合格 NARG2 谷氨酸受体调节蛋白2抗体
合格 PLAG1 多型性腺瘤基因1蛋白抗体
合格 SIRT7 沉默调节样蛋白SirT7抗体
合格 合格 AARE 氧化蛋白质水解酶
合格 DAB2IP Dab2相互作用蛋白抗体
合格 DAB2 信号转导功能磷蛋白DAB2抗体
合格 HSP40 热休克蛋白家族40抗体
合格 DAL1/EPB41L3 细胞骨架4.1蛋白家族DAL1抗体